The content on this site is intended for healthcare professionals only
Dr Jared Weiss speaks to ecancer about the KRYSTAL-1 trial. He discusses adagrasib as monotherapy or combined with cetuximab in patients with colorectal cancer harbouring a KRASG12C mutation. Initially, he talks about the rationale of the study.
Dr Weiss then discusses the methodology and results. The study proves that adagrasib is well tolerated as monotherapy and combined with cetuximab. It demonstrates promising clinical activity in heavily pretreated patients with KRASG12Cmutant CRC.
He concludes by mentioning that adagrasib and cetuximab are currently being evaluated in the 2L setting in a phase 3 trial of patients with KRASG12C-mutant CRC.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer
Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy
Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs
Revolutionising myeloma treatment through immune profiling
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC
